QUINCE THERAPEUTICS INC (QNCX) Stock Earnings & Estimates
NASDAQ:QNCX - US22053A1079 - Common Stock
1.61 USD
+0.01 (+0.31%)
1.5901 USD
-0.02 (-1.24%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 312.90% | N/A 83.10% | N/A 68.22% | N/A 39.33% | N/A 39.85% | |||||||||
| EBITDA YoY % growth | -10.32M | -12.07M -16.96% | -38.98M -222.95% | -78.56M -101.54% | -89.98M -14.54% | -50.99M 43.33% | -28.398M 44.31% | -39.969M -40.75% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -10.37M | -12.12M -16.88% | -39.17M -223.18% | -78.89M -101.40% | -90.32M -14.49% | -51.19M 43.32% | -28.72M 43.90% | -40.155M -39.82% | N/A -18.16% | N/A -10.96% | N/A 0.64% | N/A 182.96% | N/A 176.51% | N/A 119.53% | N/A 88.06% | N/A 54.81% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | -2.90 | -2.63 9.31% | -3.03 -15.21% | N/A 47.15% | N/A -91.72% | N/A 60.05% | N/A 13.76% | N/A 31.07% | N/A 9.42% | N/A 91.51% | N/A 827.27% | N/A 120.00% | N/A 32.95% | N/A 33.33% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.22 -69.79% | -0.21 24.45% | -0.20 41.40% | -0.20 14.26% | -0.20 8.50% | -0.35 -63.13% |
| Revenue Q2Q % growth | ||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -10.86M -85.22% | -10.281M 14.41% | -12.558M 13.07% | -12.626M -21.09% | -12.966M -19.39% | -22.248M -116.40% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.23 | -0.26 | 0.03 | 10.40% |
| Q1 2025 Q2Q % growth | -0.34 -30.77% | -0.23 | -0.11 | -46.52% |
| Q4 2024 Q2Q % growth | -0.28 | -0.18 | -0.10 | -56.86% |
| Q3 2024 Q2Q % growth | -0.13 13.33% | -0.21 | 0.08 | 39.31% |
| Q1 2024 Q2Q % growth | -0.26 17.51% | % | ||
| Q3 2023 Q2Q % growth | -0.15 31.82% | % | ||
| Q1 2023 Q2Q % growth | 56.22% | -0.32 | % | |
| Q4 2022 Q2Q % growth | 62.34% | -0.29 | % | |
| Q3 2022 Q2Q % growth | -0.22 69.86% | -0.29 | 0.07 | 24.05% |
| Q2 2022 Q2Q % growth | -0.51 31.08% | -0.49 | -0.02 | -3.09% |
| Q1 2022 Q2Q % growth | -0.72 7.69% | -0.56 | -0.16 | -28.90% |
| Q4 2021 Q2Q % growth | -0.78 -13.04% | -0.66 | -0.12 | -17.74% |
| Q3 2021 Q2Q % growth | -0.73 | -0.76 | 0.03 | 3.76% |
| Q2 2021 Q2Q % growth | -0.74 -23.33% | -0.77 | 0.03 | 4.29% |
| Q1 2021 Q2Q % growth | -0.78 -27.87% | -0.74 | -0.04 | -6.02% |
| Q4 2020 Q2Q % growth | -0.69 -97.14% | -0.75 | 0.06 | 7.62% |
| Q3 2020 Q2Q % growth | -0.73 -97.30% | -0.63 | -0.10 | -16.26% |
| Q2 2020 Q2Q % growth | -0.60 -5.26% | -0.63 | 0.03 | 4.84% |
| Q1 2020 Q2Q % growth | -0.61 62.11% | -0.45 | -0.16 | -36.46% |
| Q4 2019 Q2Q % growth | -0.35 | -0.41 | 0.06 | 13.65% |
| Q3 2019 Q2Q % growth | -0.37 | -0.38 | 0.01 | 2.36% |
| Q2 2019 Q2Q % growth | -0.57 | -0.38 | -0.19 | -49.42% |
| Q1 2019 Q2Q % growth | -1.61 | -0.23 | -1.38 | -586.27% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 1.64% | 9.83% | -6.91% | -20.93% |
| Revenue | N/A | N/A | N/A | N/A |